Perinatal EvidenceCompass
Prepopulated workbenchMED-265

Nonprescription/emerging psychoactive — cannabinoid/plant

Cannabidiol consumer products

Nonprescription cannabinoid exposure; distinguish from Epidiolex

Brand / product examples: CBD oils, gummies, beverages, topicals

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Cannabidiol consumer products
Entity type
consumer cannabinoid product
Active component(s)
Cannabidiol with product-variable constituents
Formulation / route / interval
Consumer oral/topical/inhaled products; quality varies
Attachment entry
Cannabidiol products
Separate monograph status
Yes — consumer products vs approved prescription cannabidiol
Identity and cross-reference
Not populated in v0.95
Inventory verification confidence
High — direct status-changing or product-specific primary source

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

2 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

C-046Provisional public source

ACOG recommends cessation of cannabis in pregnancy and lactation; observational studies associate prenatal cannabis with preterm birth, impaired growth and NICU admission, but confounding and exposure measurement limit causal estimates.

Public-source certainty descriptor
Moderate guideline consensus; low-to-moderate observational certainty
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Pregnancy and lactation
Comparator
Cannabis exposure versus no exposure
Effect or numbers carried forward

No single pooled causal estimate adopted

Limitations

THC potency, route, tobacco/polysubstance use and socioeconomic factors vary; no specific defect pattern established

Sources, citation controls, and verification state

Linked sources

PMID
40966737
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
C-047Provisional public source

FDA advises against THC, marijuana and CBD in any form during pregnancy or breastfeeding; consumer CBD may contain THC, contaminants or inaccurate amounts and is not equivalent to prescription cannabidiol.

Public-source certainty descriptor
High regulator-position certainty; very low product-specific evidence
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Pregnancy and lactation
Comparator
Consumer cannabinoid product versus no use or standardized medicine
Effect or numbers carried forward

No reliable consumer-product dose or infant exposure estimate

Limitations

Product composition and route are often unknown; topical exposure differs but does not establish safety

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending